These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 31045815)

  • 1. Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma.
    Li JP; Zhang XM; Zhang Z; Zheng LH; Jindal S; Liu YJ
    Medicine (Baltimore); 2019 May; 98(18):e15449. PubMed ID: 31045815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database.
    Chen QX; Li JJ; Wang XX; Lin PY; Zhang J; Song CG; Shao ZM
    Oncotarget; 2017 Jan; 8(4):6206-6215. PubMed ID: 28008158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
    de Nonneville A; Gonçalves A; Zemmour C; Cohen M; Classe JM; Reyal F; Colombo PE; Jouve E; Giard S; Barranger E; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
    Eur J Cancer; 2017 Oct; 84():34-43. PubMed ID: 28780480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcellular expression of MTA1, HIF1A and p53 in primary tumor predicts aggressive triple negative breast cancers: a meta-analysis based study.
    Sharaf SS; Jaganath Krishna KM; Lekshmi A; Sujathan
    J Mol Histol; 2024 Jun; 55(3):303-315. PubMed ID: 38613589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy.
    Zhang J; Wang Y; Yin Q; Zhang W; Zhang T; Niu Y
    Int J Clin Exp Pathol; 2013; 6(7):1380-91. PubMed ID: 23826420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active behavior of triple-negative breast cancer with adipose tissue invasion: a single center and retrospective review.
    Yamaguchi J; Moriuchi H; Ueda T; Kawashita Y; Hazeyama T; Tateishi M; Aoki S; Uchihashi K; Nakamura M
    BMC Cancer; 2021 Apr; 21(1):434. PubMed ID: 33879104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insight on the biological role of p53 protein as a tumor suppressor: re-evaluation of its clinical significance in triple-negative breast cancer.
    Jin MS; Park IA; Kim JY; Chung YR; Im SA; Lee KH; Moon HG; Han W; Noh DY; Ryu HS
    Tumour Biol; 2016 Aug; 37(8):11017-24. PubMed ID: 26894602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status.
    Shen S; Sun Q; Liang Z; Cui X; Ren X; Chen H; Zhang X; Zhou Y
    PLoS One; 2014; 9(6):e100664. PubMed ID: 24945253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histologic subtyping affecting outcome of triple negative breast cancer: a large Sardinian population-based analysis.
    Sanges F; Floris M; Cossu-Rocca P; Muroni MR; Pira G; Urru SAM; Barrocu R; Gallus S; Bosetti C; D'Incalci M; Manca A; Uras MG; Medda R; Sollai E; Murgia A; Palmas D; Atzori F; Zinellu A; Cambosu F; Moi T; Ghiani M; Marras V; Santona MC; Canu L; Valle E; Sarobba MG; Onnis D; Asunis A; Cossu S; Orrù S; De Miglio MR
    BMC Cancer; 2020 Jun; 20(1):491. PubMed ID: 32487046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
    Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
    PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylation of EphA2 receptor and vasculogenic mimicry is an indicator of poor prognosis in invasive carcinoma of the breast.
    Mitra D; Bhattacharyya S; Alam N; Sen S; Mitra S; Mandal S; Vignesh S; Majumder B; Murmu N
    Breast Cancer Res Treat; 2020 Jan; 179(2):359-370. PubMed ID: 31686261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between Mutation and Expression of
    Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
    Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic significance of metaplastic carcinoma of the breast (MCB)--a case controlled comparison study with infiltrating ductal carcinoma.
    Lai HW; Tseng LM; Chang TW; Kuo YL; Hsieh CM; Chen ST; Kuo SJ; Su CC; Chen DR
    Breast; 2013 Oct; 22(5):968-73. PubMed ID: 23787124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
    Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
    Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer.
    Ma F; Ding X; Fan Y; Ying J; Zheng S; Lu N; Xu B
    PLoS One; 2014; 9(11):e112765. PubMed ID: 25393310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis.
    Mills MN; Yang GQ; Oliver DE; Liveringhouse CL; Ahmed KA; Orman AG; Laronga C; Hoover SJ; Khakpour N; Costa RLB; Diaz R
    Eur J Cancer; 2018 Jul; 98():48-58. PubMed ID: 29870876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboxypeptidase A4 negatively correlates with p53 expression and regulates the stemness of breast cancer cells.
    Wang Y; Xie Y; Niu Y; Song P; Liu Y; Burnett J; Yang Z; Sun D; Ran Y; Li Y; Sun L
    Int J Med Sci; 2021; 18(8):1753-1759. PubMed ID: 33746592
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
    Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
    Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TTK is a favorable prognostic biomarker for triple-negative breast cancer survival.
    Xu Q; Xu Y; Pan B; Wu L; Ren X; Zhou Y; Mao F; Lin Y; Guan J; Shen S; Zhang X; Wang C; Zhong Y; Zhou L; Liang Z; Zhao H; Sun Q
    Oncotarget; 2016 Dec; 7(49):81815-81829. PubMed ID: 27833085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.